Esperion Therapeutics' (ESPR) Price Target Reduced to $105 at RBC

RBC Capital maintained an Outperform rating on Esperion Therapeutics (NASDAQ: ESPR) but lowered its price target to $105.00 (from $150.00). Yesterday Esperion provided investors with an updated on end of phase 2 FDA meeting minutes.

"We reduced our PT to $105 from $150 based on lowering our probability of success to market in our APP model down to 50% from 60-65% to assume more conservatism with: highly positive efficacy/ overall safety risk benefit, necessary positive CV outcomes over time down the road, and ongoing competition; i.e., CETP etc., that needs to play out," said analyst Michael J. Yee.

For an analyst ratings summary and ratings history on Esperion Therapeutics click here. For more ratings news on Esperion Therapeutics click here.

Shares of Esperion Therapeutics closed at $35.09 yesterday.

You May Also Be Interested In

• Viking Holdings (VIK) PT Raised to $82 at Mizuho
• Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
• RBC Capital Reiterates Outperform Rating on Coty Inc. (COTY), 'remains a show me story'